Navigation Links
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
Date:8/3/2010

ment several years ago of a dedicated GI business unit. Shire's proposed acquisition of Movetis brings rights to the recently approved RESOLOR in Europe as well as world-class research and development talent and a promising GI pipeline, offering additional opportunities for Shire. The acquisition will expand the growth of Shire's marketed GI product portfolio internationally.

RESOLOR is a selective, high-affinity 5-HT(4) receptor agonist specifically developed to target impaired motility associated with chronic constipation. It has composition of matter patent protection extending through 2020 and Shire estimates potential peak sales of over EUR300 million. The patients in this category are generally served by specialist gastroenterologists. Other marketed treatments for this condition are limited or have associated serious adverse effects. In addition to RESOLOR, Movetis has two projects in early clinical development and several pre-clinical leads as well as the rights to a large library of qualified lead compounds with potential for development and commercialization by Movetis in global markets in different GI indications.

About Movetis

Movetis is a European specialty GI company that is focused on improving the lives of millions of patients - both adults and children - by discovering, developing and commercialising innovative treatments targeting GI conditions with a high unmet medical need. Movetis NV was founded in Belgium in November 2006 as a spin-off of Johnson & Johnson. Movetis has a broad portfolio of GI products: Beside Resolor(R) (prucalopride), Movetis has two products in Phase 2 development and two prioritised compounds in preclinical development, all addressing important GI areas including ascites, paediatric
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
2. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
3. Shire plc Appoints Two New Board Directors
4. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
5. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
6. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
7. Shires Replenished Portfolio Drives Excellent Quarterly Performance
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. Shire Supports Rare Disease Day 2010
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Robert Harman, DVM, ... Medicine company, is proud to announce the relaunch of his ... with a new series called “ What are Stem Cells ... an honest and straightforward foundation in the basics of stem ... decision on the right type of treatment when considering regenerative ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2
... /PRNewswire-Asia-FirstCall/ -- Yongye Biotechnology,International, Inc. (OTC Bulletin Board: ... nutrients for plants and animals, located in the,People,s ... Mr. Sam Yu to be the,Company,s new chief ... Yu,replaces Larry Gilmore, who served as the Company,s ...
... 1 /PRNewswire-Asia-FirstCall/ -- Kun Run,Biotechnology, Inc., (OTC Bulletin Board: ... manufacture and sales of peptides and,peptide-based drugs, today announced ... , Revenues for the year ... $4.1 million, or 56% over revenues for the same ...
... ROCHESTER, N.Y., YORK, England and BETHESDA, Md., April ... that,continually defines the client-service standard with its inherently ... CHDX ), today announced a,partnership to provide central ... (UFH). UFH is a CAP-certified facility owned ...
Cached Biology Technology:Yongye Biotechnology Appoints New Chief Financial Officer 2Yongye Biotechnology Appoints New Chief Financial Officer 3Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 2Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 3Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 4Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 5Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 6Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 7Kun Run Biotechnology, Inc. Year-End Revenues Increase 56% to $11.6 million 8ACM Global Central Lab Announces Partnership with Chindex's United Family Hospitals in China 2ACM Global Central Lab Announces Partnership with Chindex's United Family Hospitals in China 3ACM Global Central Lab Announces Partnership with Chindex's United Family Hospitals in China 4
(Date:7/11/2014)... often develop relationships with other group members to reduce ... chacma baboons the strategy for grooming activities shows a ... published in the scientific journal Biology Letters . ... is not practiced without ulterior motives. To be groomed ... individual, while grooming another individual can provide access to ...
(Date:7/11/2014)... University, Sweden, have explored two different ways that ... leading to the formation of oxygen molecules in ... the scientific journal Nature Communications . , ... synthetic catalysts for water oxidation, which are key ... direct storage of solar energy in fuels like ...
(Date:7/11/2014)... kidney injury related to the use of hydroxyethyl starch ... molecules, according to a report in Anesthesia & ... Society (IARS). , The "total mass of HES molecules" ... renal proximal tubule cells (PTCs), concludes the laboratory study ... Wrzburg, Austria. Other factorssuch as differences in the ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... are twice as high among people born in Scotland or ... has shown. Research, conducted by the University of Edinburgh ... born in India but living in England and Wales ... Irish-born people. The findings showed too that people born ...
... research in the ESA journals Frontiers in Ecology and ... and Ecological Monographs . 1. Fuel ... invasives , Ecological Applications ... reduction methods under the U.S. National Fire and Fire Surrogate ...
... LANSING, Mich. Prenatal exposure to an insecticide commonly used ... obesity epidemic in women, according to a new study involving ... who live along and eat fish from Lake Michigan were ... DDT. The study, published as an editor,s choice in this ...
Cached Biology News:Scots and Irish at greater risk of drink-related death, study shows 2Highlights from the March editions of ESA journals 2Highlights from the March editions of ESA journals 3Exposure to insecticide may play role in obesity epidemic among some women 2
... Description: Proteinase K is a ... wide range of applications purified from the fungus ... the carboxyl group of N-substituted hydrophobic aliphatic and ... as a serine protease. Proteinase K is useful ...
Proliferin (C-14)...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
... Ascent is a dedicated fluorometer ... all kinds of assays in ... for clinical applications. Cell biology, ... all important application areas. Robot-friendly ...
Biology Products: